E. Ohman J or Asset Management AB Sells 5,200 Shares of Natera, Inc. (NASDAQ:NTRA)

E. Ohman J or Asset Management AB lowered its holdings in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 14.3% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 31,263 shares of the medical research company's stock after selling 5,200 shares during the period. E. Ohman J or Asset Management AB's holdings in Natera were worth $4,421,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the business. Smartleaf Asset Management LLC grew its holdings in shares of Natera by 50.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 657 shares of the medical research company's stock valued at $104,000 after buying an additional 220 shares during the last quarter. Steward Partners Investment Advisory LLC lifted its stake in shares of Natera by 1,328.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company's stock valued at $57,000 after buying an additional 332 shares in the last quarter. Guided Capital Wealth Management LLC purchased a new stake in shares of Natera during the 4th quarter valued at approximately $1,788,000. Teza Capital Management LLC purchased a new stake in Natera in the 4th quarter worth approximately $221,000. Finally, Van ECK Associates Corp lifted its stake in Natera by 17.4% in the 4th quarter. Van ECK Associates Corp now owns 119,673 shares of the medical research company's stock worth $18,944,000 after purchasing an additional 17,748 shares in the last quarter. Institutional investors own 99.90% of the company's stock.

Insider Activity at Natera

In other news, CEO Steven Leonard Chapman sold 6,111 shares of the firm's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $157.10, for a total value of $960,038.10. Following the completion of the sale, the chief executive officer now owns 179,071 shares in the company, valued at approximately $28,132,054.10. This trade represents a 3.30% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Michael Burkes Brophy sold 2,562 shares of the firm's stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $138.41, for a total transaction of $354,606.42. Following the completion of the sale, the chief financial officer now owns 75,557 shares of the company's stock, valued at $10,457,844.37. This trade represents a 3.28% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 68,275 shares of company stock valued at $10,075,783. Corporate insiders own 7.60% of the company's stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Barclays raised their price objective on shares of Natera from $160.00 to $190.00 and gave the company an "overweight" rating in a research report on Friday, May 9th. Royal Bank of Canada assumed coverage on shares of Natera in a research note on Thursday, March 13th. They issued an "outperform" rating and a $251.00 target price on the stock. Piper Sandler raised their price target on shares of Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a report on Thursday, May 15th. Morgan Stanley lifted their target price on shares of Natera from $176.00 to $185.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. Finally, Robert W. Baird lifted their target price on shares of Natera from $183.00 to $188.00 and gave the company an "outperform" rating in a research note on Friday, February 28th. One analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat.com, Natera presently has an average rating of "Moderate Buy" and an average price target of $184.63.

Natera Stock Performance

Natera stock traded up $0.43 during midday trading on Monday, reaching $164.19. 785,454 shares of the company traded hands, compared to its average volume of 1,407,113. The firm has a market capitalization of $22.42 billion, a price-to-earnings ratio of -93.29 and a beta of 1.74. The business has a 50 day moving average of $152.19 and a two-hundred day moving average of $158.51. Natera, Inc. has a 12 month low of $92.14 and a 12 month high of $183.00. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.09. The business had revenue of $501.83 million for the quarter, compared to the consensus estimate of $446.68 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company's quarterly revenue was up 36.5% on a year-over-year basis. During the same period last year, the firm earned ($0.56) earnings per share. As a group, research analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.